兄弟科技(002562.SZ)一季度淨利潤預增798.89%-1068.56%
格隆匯4月10日丨兄弟科技(002562.SZ)公佈,預計2022年一季度歸屬於上市公司股東的淨利潤1億元-1.3億元,同比增長798.89%-1068.56%;扣除非經常性損益後的淨利潤8935.4萬元–11935.4萬元,同比增長806.99%-1111.51%。
業績變動原因如下:1、2022年第一季度,公司“年產20000噸苯二酚、31100噸苯二酚衍生物建設項目-一期工程”相較於上年同期,其產品產能、產量、銷量和銷售價格均有不同幅度的提升,項目效益逐步釋放;
2、受原材料價格上漲、物流成本提升、國家節能減排等因素影響,公司部分維生素產品以及鉻鹽產品價格出現不同幅度的上漲,產品毛利率上升。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.